Background: The hemolytic disease of the fetus and the newborn (HDFN) is a clinical syndrome at which the basic patho-physiological disorder represents a hemolytic anemia of the fetus or the newborn.
Aim: Prompt discovery of allosensibilisation to RBC’s antigens
during pregnancy and successful management of HDFN in the Republic of
Macedonia, in order to decrease morbidity and mortality of the fetus and the
newborn.
Materials and Methods: The study comprises in total 23,800
patients, 14,858 pregnant women and 8,842 newborn babies. The
immune-hematological testing for all pregnant women has been executed in the
immunehematology laboratory at the Institute for Transfusion Medicine in
Republic of Macedonia.
Results: The screening and identification of anti-RBC’s antibodies
detected in a total of 216 alloantibodies, out of which 81% (175) had a
clinical significance. Out of the above-mentioned 164 alloantibodies (65.9%)
belong to the Rh system. The most often reason for a severe hemolytic disease
is the anti-D antibody. The HDFN symptoms of mild and moderate degrees were
demonstrated in 32.5%, and 18.9% had symptoms of severe fetal suffering, and
almost half of them (48%) were with or with mild HDFN and had no need for
therapy. In 15% it was about alloantibodies of other Rh antigens: anti-C,
anti-E and anti-c, at which in most cases there were no signs of HDFN, or it
showed weak symptoms (89%), just one case of anti-c ended with intrauterine
death.
Conclusions: Still, a hemolytic disease of the fetus and the newborn
caused by anti-D is one of the most often reasons for HDFN in most
underdeveloped countries in the world. Anti-D antibody represents a need of
intrauterine transfusion and exsanguino transfusion. Anti-c is the only
antibody that demonstrated the same potential for severe HBN as the anti-D. The
most often reason for alloimmunisation of the mother is the lack of RhIG
prophylaxis (97.8): postnatal, antenatal and in case of possible sensible
conditions during pregnancy. It is recommended to adopt a national program for
RhIG prophylaxis in the Republic of Macedonia.
Author
(s) Details
Emilija Velkova
Institute of Transfusion Medicine in Republic of Macedonia, Vodnjanska 17,
1109 Skopje, Republic of Macedonia.
Please see the book here:- https://doi.org/10.9734/bpi/acmms/v13/3716
No comments:
Post a Comment